Skip to main content
Fig. 6 | Arthritis Research & Therapy

Fig. 6

From: HM71224, a novel Bruton’s tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis

Fig. 6

HM71224 ameliorates symptoms in a mouse model of collagen-induced arthritis (CIA). As described in “Methods”, arthritis was induced by immunization with collagen. From 10 days after the second immunization, mice were treated with oral HM71224, dexamethasone (Dexa), or vehicle (Veh). Compared with vehicle, treatment with HM71224 led to dose-dependent improvements in the clinical arthritis score (a) and body weight (b). c HM71224 reduced serum IL-6 (left), and anti-type II collagen (middle) and total IgG levels (right). d The bone erosion was assessed on a hematoxylin and eosin section. HM71224 treatment reduced the degree of bone erosion. *P < 0.05, **P < 0.01, and ***P < 0.001 vs. CIA mice treated with vehicle. Ctrl (healthy) control

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us